TY - JOUR
T1 - Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy
AU - Liu, Jie
AU - Li, Bei
AU - Li, Li
AU - Ming, Xin
AU - Xu, Zhi Ping
N1 - J.L. extends sincere gratitude to the Australian Government for the Research Training Program Scholarship at the University of Queensland, and to the Innovation and Technology Commission of the Hong Kong Government for the Research Talent Hub program. This work was funded by the IDEATION program (Partner-23-159) from the Hong Kong Science & Technology Parks Corporation
Publisher Copyright:
© 2024 The Author(s). Small published by Wiley-VCH GmbH.
PY - 2024/9/19
Y1 - 2024/9/19
N2 - Immuno-stimulative effect of chemotherapy (ISECT) is recognized as a potential alternative to conventional immunotherapies, however, the clinical application is constrained by its inefficiency. Metronomic chemotherapy, though designed to overcome these limitations, offers inconsistent results, with effectiveness varying based on cancer types, stages, and patient-specific factors. In parallel, a wealth of preclinical nanomaterials holds considerable promise for ISECT improvement by modulating the cancer-immunity cycle. In the area of biomedical nanomaterials, current literature reviews mainly concentrate on a specific category of nanomaterials and nanotechnological perspectives, while two essential issues are still lacking, i.e., a comprehensive analysis addressing the causes for ISECT inefficiency and a thorough summary elaborating the nanomaterials for ISECT improvement. This review thus aims to fill these gaps and catalyze further development in this field. For the first time, this review comprehensively discusses the causes of ISECT inefficiency. It then meticulously categorizes six types of nanomaterials for improving ISECT. Subsequently, practical strategies are further proposed for addressing inefficient ISECT, along with a detailed discussion on exemplary nanomedicines. Finally, this review provides insights into the challenges and perspectives for improving chemo-immunotherapy by innovations in nanomaterials.
AB - Immuno-stimulative effect of chemotherapy (ISECT) is recognized as a potential alternative to conventional immunotherapies, however, the clinical application is constrained by its inefficiency. Metronomic chemotherapy, though designed to overcome these limitations, offers inconsistent results, with effectiveness varying based on cancer types, stages, and patient-specific factors. In parallel, a wealth of preclinical nanomaterials holds considerable promise for ISECT improvement by modulating the cancer-immunity cycle. In the area of biomedical nanomaterials, current literature reviews mainly concentrate on a specific category of nanomaterials and nanotechnological perspectives, while two essential issues are still lacking, i.e., a comprehensive analysis addressing the causes for ISECT inefficiency and a thorough summary elaborating the nanomaterials for ISECT improvement. This review thus aims to fill these gaps and catalyze further development in this field. For the first time, this review comprehensively discusses the causes of ISECT inefficiency. It then meticulously categorizes six types of nanomaterials for improving ISECT. Subsequently, practical strategies are further proposed for addressing inefficient ISECT, along with a detailed discussion on exemplary nanomedicines. Finally, this review provides insights into the challenges and perspectives for improving chemo-immunotherapy by innovations in nanomaterials.
KW - chemotherapy
KW - immunogenicity
KW - immunotherapy
KW - nanomaterial
UR - http://www.scopus.com/inward/record.url?scp=85193686107&partnerID=8YFLogxK
UR - https://onlinelibrary.wiley.com/doi/10.1002/smll.202403024
U2 - 10.1002/smll.202403024
DO - 10.1002/smll.202403024
M3 - Journal article
C2 - 38773882
AN - SCOPUS:85193686107
SN - 1613-6810
VL - 20
JO - Small
JF - Small
IS - 38
M1 - 2403024
ER -
